Eli Lilly has announced that it would bring the Mounjaro drug against obesity and diabetes to British patients, weeks after winning clearance for pre-filling it into an injection pen. The go-ahead from the Medicines & Healthcare products Regulatory Agency (MHRA) would make Britain the first major market to be supplied with the drug in the multi-shot pen, branded as Kwikpen. The pen will allow for convenient use and be good for a month’s treatment of one subcutaneous shot per week.
Tirzepatide is the active ingredient in Mounjaro, which will compete with Novo Nordisk’s Wegovy (semaglutide) injection drug in a booming weight-loss market.
To find out more, CLICK HERE.
